338840.KQ Y-Biologics, Inc.

Healthcare Biotechnology KOSDAQ
8,950 KRW
Close of Oct 31, 2026
6,330 38,000
Market cap
KRW 138B
P/E
-
P/B
8.00x
ROE
-141.2%
Dividend yield
-
Fundamental score
0.5/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 338840.KQ undervalued?

Graham number

The Graham number of Y-Biologics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Y-Biologics, Inc. fundamental analysis

3 of 21 checks passed

ROE 0/2

Low return on equity (-141.2%), below 10%.

ROA 0/1

Return on assets (-48.4%) is below the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-535.4%) is below the industry median (4.8%).

Revenue Growth 0/2

Revenue shrank 11.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (93.6%), up to 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 0/2

Cash covers 0.2 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (8.0x) is above the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Y-Biologics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Y-Biologics, Inc.

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the …

Full company profile